The ability for Medicare to negotiate lower prescription drug costs was a key component of last year's Inflation Reduction Act. The Centers for Medicare & Medicaid Services this week issued initial guidance about the requirements and parameters of the Medicare Drug Price Negotiation Program for 2026, the first year in which the negotiated prices will apply.
"Drug price negotiation is a critical piece of how this historic law improves the Medicare program," CMS Administrator Chiquita Brooks-LaSure said. "By considering factors such as clinical benefit and unmet medical need, drug price negotiation intends to increase access to innovative treatments for people with Medicare."
Complete your profile to continue reading and get FREE access to BenefitsPRO, part of your ALM digital membership.
Your access to unlimited BenefitsPRO content isn’t changing.
Once you are an ALM digital member, you’ll receive:
- Breaking benefits news and analysis, on-site and via our newsletters and custom alerts
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the property casualty insurance and financial advisory markets on our other ALM sites, PropertyCasualty360 and ThinkAdvisor
Already have an account? Sign In Now
© 2025 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
